Sure! Here's the new description with all the links removed: 👏SUBSCRIBE to my channel here: ❤️Support my channel by becoming a member: 🙋‍♂️Have questions? Ask here: 🎉Follow my community: Facebook ...

I make short, to-the-point online math tutorials. I struggled with math growing up and have been able to use those experiences to help students improve in math through practical applications and tips.

Innocent Jude Ike is a First Class graduate and the Overall Best Graduating Student of the Federal University of Wukari, Taraba State. In this interview with ...

The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. In its latest offensive, the agency has unleashed a fresh set of 30 warning letters targeting ...

People who order low-cost versions of the wildly popular weight-loss drugs Wegovy and Zepbound from so-called compounding pharmacies might soon see disruptions in their medication. The U.S. Food and ...

OpenLoop, a company providing operational and tech services to telehealth companies, and compounding pharmacy Triad Rx are being sued in a class action for selling oral tirzepatide. The complaint (PDF ...

GLP-1 weight-loss drugs are now the focus of a heated legal battle, with a leading drugmaker warning that copycat versions pose a risk to patient safety. "When you go and try to source raw materials ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

A high-profile fight in the world of compounded drugs looks like it has been resolved, with telehealth firm Hims & Hers (HIMS) backing off a plan to offer a knockoff Wegovy pill for as little as $49 ...

FDA enforcement will focus on restricting GLP-1 APIs in mass-marketed, nonapproved compounded products to address unverifiable quality, safety, and efficacy under the FD&C Act. Appropriate compounding ...

Hims & Hers' decision to stop offering the $49 version of Novo Nordisk A/S' (NYSE: NVO) Wegovy comes days after the company launched it. "Since launching the compounded semaglutide pill on our ...

Hims & Hers (HIMS) shares dropped 16% after-hours as FDA plans to restrict compounded GLP-1 ingredients and HHS referred Hims to DOJ. Hims projected $725M in weight-loss revenue for 2025 from total ...